Y-mAbs Therapeutics SG&A Expenses 2017-2025 | YMAB

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

Y-mAbs Therapeutics sg&a expenses from 2017 to 2025. Sg&a expenses can be defined as the sum of all selling, general and administrative expenses.

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

Y-mAbs Therapeutics sg&a expenses from 2017 to 2025. Sg&a expenses can be defined as the sum of all selling, general and administrative expenses.

Related Stocks
Company Name	Market Cap
AstraZeneca (AZN)	$229.4B
Amgen (AMGN)	$163.2B
Gilead Sciences (GILD)	$142.1B
Vertex Pharmaceuticals (VRTX)	$120.3B
Bristol Myers Squibb (BMY)	$95.4B
CSL (CSLLY)	$86B
GSK (GSK)	$76.9B
Regeneron Pharmaceuticals (REGN)	$60.3B
Alnylam Pharmaceuticals (ALNY)	$43.1B
Argenex SE (ARGX)	$36.6B
BioNTech SE (BNTX)	$26.8B
Royalty Pharma (RPRX)	$21B
Insmed (INSM)	$19.9B
Biogen (BIIB)	$18.7B
Illumina (ILMN)	$17.2B
Incyte (INCY)	$15B
Genmab (GNMSF)	$14.7B
Genmab (GMAB)	$14.5B
Moderna (MRNA)	$12.6B
QIAGEN (QGEN)	$11.4B
BioMarin Pharmaceutical (BMRN)	$11.2B
Swedish Orphan Biovitrum (BIOVF)	$10.6B
Ascendis Pharma (ASND)	$10B
Exelixis (EXEL)	$9.9B
Bio-Techne Corp (TECH)	$9.1B
Exact Sciences (EXAS)	$9B
Verona Pharma American Depositary Share (VRNA)	$9B
Blueprint Medicines (BPMC)	$8.3B
Roivant Sciences (ROIV)	$7.8B
Legend Biotech (LEGN)	$7.5B